No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The Glucagon Like Peptide 2 Receptor (GLP-2R) is a G-protein coupled receptor that is involved in the regulation of glucose homeostasis and energy balance. It is a target for the development of drugs for the treatment of metabolic diseases such as diabetes and obesity. GLP-2R agonists are also being investigated for their potential to treat diseases of the central nervous system, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.
GLP-2R agonists are being developed by a number of pharmaceutical companies, including Novo Nordisk, Eli Lilly, Merck, and AstraZeneca. These companies are researching the potential of GLP-2R agonists to treat a variety of diseases, including metabolic and neurological disorders. Additionally, several biotechnology companies are developing GLP-2R agonists for the treatment of metabolic diseases. Show Less Read more
